Obstructive Sleep Apnea - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Obstructive Sleep Apnea - Pipeline Review, H1 2016', provides an overview of the Obstructive Sleep Apnea pipeline landscape. The report provides comprehensive information on the therapeutics under development for Obstructive Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obstructive Sleep Apnea and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Obstructive Sleep Apnea - The report reviews pipeline therapeutics for Obstructive Sleep Apnea by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Obstructive Sleep Apnea therapeutics and enlists all their major and minor projects - The report assesses Obstructive Sleep Apnea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Obstructive Sleep Apnea Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Obstructive Sleep Apnea - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Obstructive Sleep Apnea pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Obstructive Sleep Apnea Overview 7 Therapeutics Development 8 Pipeline Products for Obstructive Sleep Apnea - Overview 8 Obstructive Sleep Apnea - Therapeutics under Development by Companies 9 Obstructive Sleep Apnea - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Obstructive Sleep Apnea - Products under Development by Companies 13 Obstructive Sleep Apnea - Companies Involved in Therapeutics Development 14 Galleon Pharmaceuticals 14 RespireRx Pharmaceuticals Inc. 15 SK Biopharmaceuticals Co., Ltd. 16 Vivus, Inc. 17 Obstructive Sleep Apnea - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Combination Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 25 Drug Profiles 27 (phentermine + topiramate) ER - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 dronabinol - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 GAL-475 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 GAL-475 Backups - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 SKL-N05 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Obstructive Sleep Apnea - Recent Pipeline Updates 35 Obstructive Sleep Apnea - Dormant Projects 44 Obstructive Sleep Apnea - Discontinued Products 45 Obstructive Sleep Apnea - Product Development Milestones 46 Featured News & Press Releases 46 Jun 08, 2015: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of EDS Associated with Narcolepsy or with OSA 46 May 14, 2015: VIVUS Announces Scientific Presentations 46 May 15, 2014: VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists 47 Jul 01, 2013: VIVUS Announces Initial Availability of Qsymia Through Certified Retail Pharmacies 48 Nov 12, 2012: Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules 49 Jan 09, 2012: VIVUS Provides Update On Regulatory Status Of Qnexa 49 Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa 50 Jan 07, 2010: VIVUS Announces Positive Results from Phase II Study Of Qnexa In Obstructive Sleep Apnea 50 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Number of Products under Development for Obstructive Sleep Apnea, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Obstructive Sleep Apnea - Pipeline by Galleon Pharmaceuticals, H1 2016 14 Obstructive Sleep Apnea - Pipeline by RespireRx Pharmaceuticals Inc., H1 2016 15 Obstructive Sleep Apnea - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 16 Obstructive Sleep Apnea - Pipeline by Vivus, Inc., H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Assessment by Combination Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Obstructive Sleep Apnea Therapeutics - Recent Pipeline Updates, H1 2016 35 Obstructive Sleep Apnea - Dormant Projects, H1 2016 44 Obstructive Sleep Apnea - Discontinued Products, H1 2016 45
List of Figures
Number of Products under Development for Obstructive Sleep Apnea, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Top 10 Targets, H1 2016 20 Number of Products by Stage and Top 10 Targets, H1 2016 20 Number of Products by Top 10 Mechanism of Actions, H1 2016 22 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 22 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Stage and Molecule Types, H1 2016 25
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to driveRead More...
U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposableRead More...
Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing apRead More...
Global heat transfer fluids market size is likely to be valued at USD 3.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing demand for for heat recovery management in industries such as metal processing, pharmaceuticaRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.